BRCA1 and ovarian cancer: Oncomine®BRCA1/2 Panel accurately detects pathogenic BRCA1/2 variants in patients with breast and/or ovarian cancer, so is feasible for use in cancer genome research and diagnostic purposes in a clinical setting.